The FDA has granted premarket approval for the Allurion gastric balloon system, a swallowable weight loss device that requires no surgery, endoscopy or anesthesia.
The system, developed by Allurion Technologies, uses a capsule that expands into a balloon in the stomach and self-empties after about four months. A second capsule can be administered two months after the first passes, according to a Feb. 23 news release.
The device is designed for use during a 15-minute office visit and offers a four-month treatment period from a single administration. The company previously paused sales of the device in France before reintroducing it last year. Outside the U.S., it has been used in more than 200,000 patients.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
